CD300A

Across TCGA pan-cancer cohorts, CD300A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CD300A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CD300A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CD300A is over-expressed in tumor.

CCRCC, HNSC, and LSCC are the cancer types where CD300A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD300A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	+1.024	<.001	12	view →
HNSC	All	IV	+0.536	<.001	11	view →
LSCC	Female	III,IV	+0.793	<.001	9	view →
LUAD	Male	II,III,IV	+0.314	<.001	6	view →
PDAC	Female	All	+0.631	.003	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CD300A–CCRCC

Open the CCRCC breakdown →